Agios Pharmaceuticals (AGIO) Return on Sales (2016 - 2025)
Agios Pharmaceuticals' Return on Sales history spans 14 years, with the latest figure at 5.41% for Q4 2025.
- For Q4 2025, Return on Sales rose 358.0% year-over-year to 5.41%; the TTM value through Dec 2025 reached 7.67%, down 2604.0%, while the annual FY2025 figure was 7.64%, 2610.0% down from the prior year.
- Return on Sales reached 5.41% in Q4 2025 per AGIO's latest filing, up from 8.03% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 105.75% in Q3 2024 to a low of 14.71% in Q1 2023.
- Average Return on Sales over 5 years is 3.88%, with a median of 8.51% recorded in 2024.
- Peak YoY movement for Return on Sales: soared 11809bps in 2024, then plummeted -11378bps in 2025.
- A 5-year view of Return on Sales shows it stood at 44.14% in 2021, then crashed by -99bps to 0.4% in 2022, then plummeted by -3490bps to 13.51% in 2023, then soared by 33bps to 9.0% in 2024, then skyrocketed by 40bps to 5.41% in 2025.
- Per Business Quant, the three most recent readings for AGIO's Return on Sales are 5.41% (Q4 2025), 8.03% (Q3 2025), and 9.04% (Q2 2025).